Use of uap inhibitors to inhibit flux through the hexosamine biosynthetic pathway

A pharmaceutical composition comprising a compound or pharmaceutically acceptable salt, solvate, anomers or hydrate thereof:

• wherein X is CO, SO2 or CH2;
• R6, R7, R8, R9, are each independently H or CO(CH2)nCH3;
• n is 0-16;
• R is selected from the group consisting of
• wherein V, W, X, Y, Z are, each independently, C, N, S, or O,
• R1, R2, R3, R4, R5 are, each independently, absent, —H, —(CH2)mCH3 where m=0-6 including branched alkyls, —Br, —Cl, —F, —I, —NH2, —SH, —NO2, —NHSO2Ra where Ra is alkyl or branched alkyl, —SO2NHRb where Rb is alkyl or branched alkyl, —OH, —ORc where Rc is alkyl or branched alkyl or alkyl ester, —NHRd where Rd is alkyl or branched alkyl or amide, —OCF3, —COOH, or —COORe where Re is alkyl or branched alkyl, R′ is substituted or unsubstituted alkyl, which includes heteroatoms NH, O, or S, i is 0 to 16, k is 0 to 10, and
• a pharmaceutically acceptable carrier.